Alumis (ALMS) Gains from Sales and Divestitures (2024 - 2025)

Alumis (ALMS) reported Gains from Sales and Divestitures of $2583.0 for Q4 2025, down 87.29% year-over-year from $20322.0 in Q4 2024, and little changed quarter-over-quarter from $2583.0 in Q3 2025.

Alumis (ALMS) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends

Alumis (ALMS) has 2 years of Gains from Sales and Divestitures data on file, last reported at $2583.0 in Q4 2025.

  • Gains from Sales and Divestitures for Q4 2025 came in at $2583.0, down 87.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $2583.0 (down 87.29% YoY), and the FY2025 annual result was $2583.0, down 87.29% from the prior year.
  • Gains from Sales and Divestitures was little changed at $2583.0 in Q4 2025 per ALMS's latest filing, from $2583.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $20322.0 in Q4 2024 and troughed at $2583.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Alumis 1.99 Bn 1.90 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 2,583.00
Dec 31, 2025 2,583.00
Sep 30, 2025 2,583.00
Sep 30, 2025 2,583.00
Jun 30, 2025 2,583.00
Jun 30, 2025 2,583.00
Mar 31, 2025 2,583.00
Mar 31, 2025 2,583.00
Dec 31, 2024 20,322.00
Dec 31, 2024 20,322.00
Sep 30, 2024 16,445.00
Sep 30, 2024 16,445.00
Jun 30, 2024 12,567.00
Jun 30, 2024 12,567.00